{"version":1,"type":"rich","provider_name":"Libsyn","provider_url":"https:\/\/www.libsyn.com","height":90,"width":600,"title":" Lower LDL-C for Longer? Defining the Optimal Timing and Intensity of Rx","description":" Should statin therapy be routinely initiated in middle\u2011aged adults with at least one atherosclerotic cardiovascular disease risk factor and LDL\u2011C levels above 100 mg\/dL? Observational data consistently shows that lower LDL-C and non-HDL-C levels are associated with substantially reduced risks of atherosclerotic vascular disease. In the absence of randomized trial data in younger and middle-aged adults with low 10\u201330\u2011year risk, the role of additional risk stratification tools\u2014such as hsCRP and coronary artery calcium scoring\u2014becomes critical in guiding individualized decisions about when to begin lipid-lowering pharmacotherapy.  In this interview, William E. Boden MD, FACC and\u202fRoger S. Blumenthal, MD, FACC discuss \u2018Lower LDL-C for Longer? Defining the Optimal Timing and Intensity of Rx\u2019.  ","author_name":"ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research","author_url":"http:\/\/accelaccorg.libsyn.com\/website","html":"